{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:13:50Z","timestamp":1789676030871,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["109CM-TMU-08"],"award-info":[{"award-number":["109CM-TMU-08"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bbrc.2026.153646","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:05:38Z","timestamp":1773828338000},"page":"153646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual-specificity phosphatase 21 enhances the sensitivity of imatinib-resistant chronic myeloid leukemia cells to ponatinib through GATA-1-mediated erythroid differentiation"],"prefix":"10.1016","volume":"814","author":[{"given":"Chih-Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kuei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5553-112X","authenticated-orcid":false,"given":"Huei-Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153646_bib1","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2026.153646_bib2","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-the surveillance, epidemiology, and end results database, 2000-2019","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2026.153646_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2026.153646_bib4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3390\/ph17070894","article-title":"Enhanced antitumor activity by the combination of dasatinib and selinexor in chronic myeloid leukemia","volume":"17","author":"Spampinato","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2026.153646_bib5","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.3390\/ijms25073693","article-title":"FL118 is a potent therapeutic agent against chronic myeloid leukemia resistant to BCR-ABL inhibitors through targeting RNA helicase DDX5","volume":"25","author":"Takeda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153646_bib6","article-title":"Ponatinib: an update on its drug targets, therapeutic potential and safety","volume":"1878","author":"Gao","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2026.153646_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.2023022538","article-title":"BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib","volume":"144","author":"Leyte-Vidal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153646_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","article-title":"Genetic mechanisms of chronic myeloid leukemia blastic transformation","volume":"7","author":"Skorski","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.bbrc.2026.153646_bib9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1128\/MCB.23.4.1278-1291.2003","article-title":"Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-Induced apoptosis by downregulation of c-FLIP","volume":"23","author":"Hietakangas","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.153646_bib10","article-title":"Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.153646_bib11","doi-asserted-by":"crossref","first-page":"C37","DOI":"10.1152\/ajpcell.00130.2013","article-title":"Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib","volume":"306","author":"Huang","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bbrc.2026.153646_bib12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jcp.21627","article-title":"c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors","volume":"218","author":"Huang","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbrc.2026.153646_bib13","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/sj.onc.1210034","article-title":"Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition","volume":"26","author":"Jacquel","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.153646_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0006-291X(02)02488-9","article-title":"Identification and characterization of two novel low-molecular-weight dual specificity phosphatases","volume":"298","author":"Hood","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.153646_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbamcr.2018.09.002","article-title":"Dual-specificity MAP kinase phosphatases in health and disease","volume":"1866","author":"Seternes","year":"2019","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"10.1016\/j.bbrc.2026.153646_bib16","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.3390\/ijms26178342","article-title":"Dual-specificity protein phosphatases targeting extracellular signal-regulated kinases: friends or foes in the biology of cancer?","volume":"26","author":"Tubita","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153646_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.26665","article-title":"RNA interference against cancer\/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma","volume":"59","author":"Deng","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2026.153646_bib18","first-page":"640","article-title":"Expression of dual-specificity phosphatases in TGF\u00df1-induced EMT in SKOV3 cells, Turk","volume":"53","author":"G\u00fcler","year":"2023","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.bbrc.2026.153646_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151488","article-title":"Dual-specific phosphatase DUSP21 is a novel negative feedback regulator for STAT3","volume":"752","author":"Shikata","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.153646_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/15384101.2015.1120925","article-title":"Coordinating cell proliferation and differentiation: antagonism between cell cycle regulators and cell type-specific gene expression","volume":"15","author":"Ruijtenberg","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2026.153646_bib21","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s10495-016-1264-z","article-title":"A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells","volume":"21","author":"Chen","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbrc.2026.153646_bib22","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.18632\/oncotarget.692","article-title":"All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib","volume":"3","author":"Cassuto","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.153646_bib23","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood-2004-04-1603","article-title":"Global regulation of erythroid gene expression by transcription factor GATA-1","volume":"104","author":"Welch","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153646_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12920-016-0218-1","article-title":"A 19-Gene expression signature as a predictor of survival in colorectal cancer","volume":"9","author":"Abdul Aziz","year":"2016","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.bbrc.2026.153646_bib25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2159-8290.CD-13-0235","article-title":"MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction","volume":"4","author":"Asmussen","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.153646_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood.V63.1.195.195","article-title":"Specific globin mRNAs in human erythroleukemia (K562) cells","volume":"63","author":"Miller","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153646_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.153646_bib28","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.4161\/cc.9.10.11602","article-title":"GATA-1 directly regulates p21 gene expression during erythroid differentiation","volume":"9","author":"Papetti","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2026.153646_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jcp.22074","article-title":"Activin A induction of erythroid differentiation through MKK6-p38alpha\/p38beta pathway is inhibited by follistatin","volume":"223","author":"Huang","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbrc.2026.153646_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113219","article-title":"Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib","volume":"417","author":"Chen","year":"2022","journal-title":"Exp. Cell Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26004109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26004109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:55:48Z","timestamp":1789674948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26004109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S0006291X26004109"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153646","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-specificity phosphatase 21 enhances the sensitivity of imatinib-resistant chronic myeloid leukemia cells to ponatinib through GATA-1-mediated erythroid differentiation","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153646"}}